BLOG
US passes the Biosecure Act
The US House of Representatives passed the Biosecure Act , which intends to restrict US Pharma companies from doing business with certain Chinese biotech firms with a grandfathering clause of eight years.
The act mentioned names of five Chinese companies- BGI Genomics, MGI Tech, Complete Genomics, WuXi AppTec and Wuxi Biologics for the regulation.
The bill will now head to the US Senate for voting and if it becomes law, then it provides an opportunity for Indian CDMO players. Global pharma companies have already started taking action despite the legislation not yet even a law.
As per F&S report, India CRAMs Industry is currently at USD 7 Billion and is poised to expand at a CAGR of 14% till FY2028 which will be highest amongst other regions. China CRAMs Industry size is USD 25 Billion.
Most of the players have undergone significant capex expansion in recent years with the combined capex figure for Divi’s, Syngene, Piramal Pharma, Hikal and GLS stood at Rs 9600 crore during FY21-24. Suffice to say that they are well prepared to cater to the incremental opportunities stemming from Biosecure Act.
Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Related content
Blogs
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Articles - Stocks
Advantages and Disadvantages of NPS
It is a long established fact that a reader will be distracted by the readable content of a page when looking at it...
Video
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.
Video - Stocks
What is Book Value?
Book Value Explained – Find out what is book value in stocks in this video by ICICIdirect.com.